2024-10-18 - Analysis Report
## Gilead Sciences Inc. (GILD) Stock Analysis Report

**Company Overview:** Gilead Sciences Inc. is a biopharmaceutical company that develops, manufactures, and markets drugs for the treatment of life-threatening and chronic diseases.

**Performance Analysis:**

1. **Performance vs. S&P 500 (VOO):**
    * GILD has significantly underperformed the S&P 500 (VOO) with a cumulative return of -10.38% compared to VOO's 136.93%. 
    * This results in a relative divergence of -147.31, which falls within the 5.35 percentile of its historical range.
2. **Recent Price Movement:**
    * **Closing Price:** $86.75
    * **5-Day Moving Average:** $85.52
    * **20-Day Moving Average:** $84.50
    * **60-Day Moving Average:** $79.76
    * The stock is trading above its 5-day, 20-day, and 60-day moving averages, indicating potential upward momentum.
3. **Technical Indicators:**
    * **RSI (72.16):** Indicates overbought conditions, suggesting potential for a short-term correction.
    * **PPO (-0.11):** Shows a bearish trend.
    * **Delta_Previous_Relative_Divergence (-3.06):** Indicates a short-term downward trend.
    * **Expected_Return (0.0%):**  Currently, the model predicts a 0% expected return over the next five years, with no significant expected outperformance compared to the S&P 500.
4. **Recent Earnings and Outlook:**
    * **Latest Earnings:** 
        | Date | EPS | Revenue |
        |---|---|---|
        | 2024-08-08 | 1.29 | 6.95 B$ |
        | **Expected EPS:** (Data not provided)
    * The most recent earnings report shows a positive EPS of 1.29 and revenue of 6.95 billion USD. 
    * While the company delivered solid results in the recent quarter, it's important to note that the lack of expected EPS data makes it challenging to gauge the market's sentiment regarding the company's future prospects.

5. **News and Recent Issues:**
    * **Recent Market Outlook:**
        * **Analyst Opinions:** 
        * **Performance Highlights:**
    * **FINBOLD Insights:** 
    * **News Sources:**

**Overall Analysis:**

Gilead Sciences is currently facing challenges with its performance, significantly lagging behind the S&P 500. While the recent earnings report shows positive results, the lack of expected EPS data creates uncertainty about future performance. Technical indicators suggest potential short-term corrections and a bearish trend, although recent price movement above moving averages indicates potential upward momentum. The 0% expected return suggests limited upside potential compared to the S&P 500 over the next five years. It's recommended to consider a more comprehensive evaluation of the company's long-term growth prospects, including its pipeline, competitive landscape, and regulatory environment, before making any investment decisions.
